CareDx Reports Preliminary Financial Results for 2024
CareDx, Inc. (Nasdaq: CDNA) has disclosed preliminary, unaudited financial results for the fourth quarter and entire year 2024. As a leading healthcare solutions company focused on transplant patients, CareDx highlighted a remarkable increase in revenue that reflects its ongoing commitment to progress in the transplant field.
Fourth Quarter 2024 Highlights
In the fourth quarter, CareDx anticipates revenue to range between $85 million and $86 million, marking a significant year-over-year growth of approximately 30%. Notably, revenue generated from testing services is poised to be between $62.5 million and $63.5 million, representing a 35% increase compared to the previous year.
Testing Services Volume Growth
The demand for testing services has also risen, with an estimated volume of around 45,500 tests performed, which is a 14% increase from the same quarter last year. This growth can be attributed to the company’s focus on enhancing patient care and advancing solutions that benefit transplant patients and their families.
Revenue Breakdown
In addition, CareDx expects its Digital Solutions and Products to each contribute around $11.4 million to the overall revenue for the fourth quarter. While the GAAP loss is projected to be between $32 million and $34 million, the adjusted EBITDA is anticipated to fall within the range of $8 million to $9 million.
Full Year 2024 Financial Overview
For the full year 2024, CareDx estimates the revenue to fall between $332 million and $333 million. The GAAP loss for the year is anticipated to be between $58 million and $60 million, while the adjusted EBITDA is expected to show notable growth, estimated between $25 million and $26 million.
Improved Financial Position
As of December 31, 2024, CareDx expects to see its available cash, cash equivalents, and marketable securities to total approximately $261 million. This is a substantial increase of around $26 million compared to the previous year, showcasing the company's strengthening financial position.
Looking Ahead: 2025 Revenue Guidance
As CareDx continues to build momentum for its offerings, the company is optimistic about achieving revenue of $370 million in 2025. The focus remains on expanding kidney surveillance testing, with the recent addition of 30 sales and marketing professionals, enhancing the company's outreach and effectiveness in the field.
CEO Insights on Future Growth
“We remain dedicated to serving transplant patients, and it's exciting to see our testing services volume grow for the sixth consecutive quarter,” stated John W. Hanna, CareDx President and CEO. He further emphasized the company's efforts to achieve $500 million in revenue and 20% adjusted EBITDA by 2027, setting a clear vision for sustained growth and impact in the industry.
About CareDx
CareDx, Inc. specializes in offering innovative and precision medicine solutions for transplant patients. By focusing on the discovery, development, and commercialization of clinically differentiated healthcare solutions, CareDx serves patients and caregivers throughout their pre-and post-transplant journeys.
Frequently Asked Questions
What are CareDx's projected revenues for 2024?
CareDx anticipates revenues for 2024 to be between $332 million and $333 million.
How does CareDx plan to grow its revenue in 2025?
CareDx plans to achieve a revenue of $370 million in 2025 through expanded offerings and increased testing services.
What financial results are expected for Q4 2024?
Q4 2024 revenue is projected to be between $85 million and $86 million, with testing services revenue expected to be around $62.5 million to $63.5 million.
What is CareDx's adjusted EBITDA for 2024?
CareDx expects its adjusted EBITDA for 2024 to range from $25 million to $26 million.
What initiatives has CareDx undertaken to improve patient care?
CareDx has expanded its sales and marketing team by approximately 30 professionals to enhance outreach and support for kidney surveillance testing.
